FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.

Slides:

Advertisements

Similar presentations

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

Advertisements

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7-8, 2005 By: Dr. Robin Robinson (HHS/OPHEP)

Vaccines and Related Biological Products

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

HHS Pandemic Influenza Vaccine Program VRBPAC Meeting Robin Robinson, Ph.D. Director, BARDA Deputy Assistant Secretary, ASPR November 14, 2012.

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Pre-2003 Pandemic Influenza Vaccine Goal & Strategy

Tom Shimabukuro, MD, MPH, MBA Immunization Safety Office Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious.

CDC Director’s Perspective Immunization Program Managers Meeting Thomas R. Frieden, MD, MPH Director, CDC Administrator, ATSDR.

National Vaccine Advisory Committee June 7, 2005 Pandemic Influenza Vaccine Research and Development Linda C. Lambert Chief, Respiratory Diseases Branch.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

0 HHS Influenza Vaccine Projects for NVAC Meeting November 29-30, 2005 By: Dr. Robin Robinson Sr. Project Officer ORDC/OPHEP/DHHS.

Adult Immunization 2010 Influenza Segment This material is in the public domain This information is valid as of May 25, 2010.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Why Vaccines Are Important for Children

INFLUENZA VACCINE Group 1 Zainab Ashfaq Bushra Abbas Ahtasham Danish.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

1 Pandemic Influenza Vaccine Development Pandemic Influenza Vaccine Development sanofi pasteur R&D, France Frederick R. Vogel, Ph.D.

Vaccines and Related Biological Products Advisory Committee Meeting

HealthSanté CanadaCanada Influenza Prevention and Control in Canada Arlene King, MD, MHSc, FRCPC Director, Immunization and Respiratory Infections Division,

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

0 H1N1 Vaccines VRBPAC Meeting Robin Robinson, Ph.D. HHS/ASPR/BARDA Director July 23, 2009.

Advanced Vaccine Development: the Challenge is in the Details

Influenza Vaccine Development

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

Immunization in the Time of H1N1 Anne Schuchat, MD Rear Admiral, US Public Health Service Director, National Center for Immunization and Respiratory Diseases.

Use of Immunogenicity Data to Assess Vaccine Effectiveness Cara R. Fiore, Ph D Microbiologist, Master Reviewer Office of Vaccines Research and Review Center.

Rapid Containment: Pharmaceutical Measures (Phase 4 & 5)

Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.

THE NATIONAL INFLUENZA VACCINE SUMMIT: UPDATE Raymond A. Strikas, M.D. Immunization Services Division National Immunization Program Coordinating Center.

CDC’s Advisory Committee on Immunization Practices (ACIP) CDC’s Advisory Committee on Immunization Practices (ACIP) How is Vaccine Policy Made? William.

Vaccines for Children Program Stockpile Status National Vaccine Advisory Committee February 4, 2010 Washington, DC Lance E Rodewald, MD Director, Immunization.

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Office of Public Health Preparedness and Response Division of Strategic National Stockpile Ben Erickson Public Health Analyst Inventory Management Tracking,

Food and Drug Administration

America Responds: An HHS 2009-H1N1 Retrospective to Advance All Hazards Preparedness Discussion with the National Vaccine Advisory Committee June 3, 2010.

1 Licensure of Pandemic Influenza Vaccines: Demonstration of Effectiveness Vaccines and Related Biological Products Advisory Committee Meeting February.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Q-Pan H5N1 Vaccine) Manufactured by GlaxoSmithKline Vaccines and Related Biological Products Advisory.

Planning for the Influenza Season: Will it be Rain, Shine, or Hurricane? National Vaccine Advisory Committee June 7, 2005 Washington, DC Raymond.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

INFLUENZA UPDATE DEBBYE ROSEN ADULT IMMUNIZATION COORDINATOR CONNECTICUT DEPARTMENT OF PUBLIC HEALTH

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER Regulatory Approaches & Activities To Support Licensure of Pandemic (H1N1) 2009 Vaccine.

Influenza A (H1N1) Vaccine Vaccines and Related Biological Products Advisory Committee Meeting, 23 July 2009 Raburn Mallory, M.D. Proprietary Vaccines.

Samar Musmar,MD,FAAFP Vice Dean for Clinical Affairs An-Najah National University Faculty of Medicine Head, Medicine and Society Dep. Flu Vaccination in.

Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.

Plans to Assess the Effectiveness of Seasonal and Pandemic Influenza Vaccines during David Shay MD, MPH (Prevention Assessment and Modeling Team.

Gateway to the Future: Improving the National Vital Statistics System St. Louis, MO June 6 th – June 10 th, 2010 Abortion Surveillance in the United States:

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute.

SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.

Update on the Development of a Group A Streptococcal Vaccine Fran A. Rubin, Ph.D. Program Officer for Group A Streptococci Respiratory Diseases Branch.

Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.

1 H5N1 Influenza Virus Vaccine, A/Vietnam/1203/2004 (Clade 1) VRBPAC Presentation Kenneth P. Guito, MBA Strategic Project Office.

Scientific Basis for Review of Varicella Zoster Immune Globulin Products Blood Products Advisory Committee July 21, 2005 Dorothy Scott, M.D. OBRR/CBER.

Adult Immunization: Goals, Challenges, and a role for the National Vaccine Advisory Committee October 22, 2007 Raymond A. Strikas, MD National Vaccine.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.

Tammra L. Morrison, RN Communicable Disease Coordinator Christopher J. Smith, RS, MPA Director of Environmental Health Rodney Dancy Community Preparedness.

Vaccination Info. Journal of immunology Vaccination of HCWs was associated with reductions in total patient mortality from 17% to 10% (odds ratio [OR],

1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

CVD Testing the H1N1 Pandemic Flu Vaccines Mini-Med School Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September.

NIAID Antimicrobial Resistance Research Efforts: Opportunities for the Global Community Dennis M. Dixon, PhD Chief, Bacteriology and Mycology Branch Division.

Pandemic Influenza Vaccine Manufacture Preparedness Lin Su Sinovac Biotech Co., Ltd.

1 Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming With an.

ACIP Recommendations Update for the U.S. Influenza Season

Vaccines and Related Biological Products Advisory Committee Meeting

Case presentation of non-clinical and clinical development of vaccines

Influenza algorithm for determining recommended 2009–2010 influenza immunization. a Contraindications: please refer to page 7 of the policy statement for.

Presentation transcript:

FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009 H1N1 Influenza Virus Overview of Clinical Studies by NIAID/NIH July 23, 2009 Linda C. Lambert, Ph.D. Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases National Institutes of Health Discussion of Clinical Trials to Support use of Vaccines against the 2009 H1N1 Influenza Virus Overview of Clinical Studies by NIAID/NIH July 23, 2009 Linda C. Lambert, Ph.D. Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases National Institutes of Health

Outline NIAID H1N1 vaccine trials Initial 5 protocols Clinical infrastructure TIV study in pregnant women NIAID H1N1 vaccine trials Initial 5 protocols Clinical infrastructure TIV study in pregnant women

H1N1 Outbreak: Initial Response FDA, NIAID, BARDA initiated regular discussions on vaccine-related issues FDA - licensure discussions with companies BARDA - US H1N1 vaccine supply US stockpile clinical trial material NIAID - identify options for USG clinical trial support; assess trial capacity FDA, NIAID, BARDA initiated regular discussions on vaccine-related issues FDA - licensure discussions with companies BARDA - US H1N1 vaccine supply US stockpile clinical trial material NIAID - identify options for USG clinical trial support; assess trial capacity

Areas identified for possible NIAID trial support Licensure or EUA Special populations young infants, pregnant women, immunocompromised Help inform policy, “gap” areas accelerate availability of 1 vs. 2 dose data in different populations administration with seasonal influenza vaccine different dosing intervals use of different adjuvanted products mixing stockpiled vaccines and adjuvant Licensure or EUA Special populations young infants, pregnant women, immunocompromised Help inform policy, “gap” areas accelerate availability of 1 vs. 2 dose data in different populations administration with seasonal influenza vaccine different dosing intervals use of different adjuvanted products mixing stockpiled vaccines and adjuvant

NIAID H1N1 Vaccine Trials: Initial Studies 5 separate protocols Data not intended to support licensure Complimentary to company planned trials 1 vs. 2 doses of unadjuvanted CSL vaccine in healthy adults 1 vs. 2 doses of unadjuvaned SP vaccine in healthy adults 1 vs. 2 doses of unaduvanted SP vaccine in healthy children co- vs. sequential administration of TIV and H1N1 vaccine in adults co- vs. sequential administration of TIV and H1N1 vaccine in children 5 separate protocols Data not intended to support licensure Complimentary to company planned trials 1 vs. 2 doses of unadjuvanted CSL vaccine in healthy adults 1 vs. 2 doses of unadjuvaned SP vaccine in healthy adults 1 vs. 2 doses of unaduvanted SP vaccine in healthy children co- vs. sequential administration of TIV and H1N1 vaccine in adults co- vs. sequential administration of TIV and H1N1 vaccine in children v

NIAID H1N1 Response: Clinical Trial Infrastructure Vaccine and Treatment Evaluation Units (VTEUs) consortium of individual contracts ready resource for the conduct of clinical research contracts academic centers and other organizations subcontracts Broad range of capabilities phase I, II, III, and IV trials bacterial, viral, parasitic vaccines novel delivery systems, compare formulations/dosing schedules therapeutics, immunotherapeutics targeted surveillance, burden of disease studies Access to different populations healthy adults and elderly, pediatric populations special populations (e.g. immunocompromised, pregnant women) Vaccine and Treatment Evaluation Units (VTEUs) consortium of individual contracts ready resource for the conduct of clinical research contracts academic centers and other organizations subcontracts Broad range of capabilities phase I, II, III, and IV trials bacterial, viral, parasitic vaccines novel delivery systems, compare formulations/dosing schedules therapeutics, immunotherapeutics targeted surveillance, burden of disease studies Access to different populations healthy adults and elderly, pediatric populations special populations (e.g. immunocompromised, pregnant women)

Credit: AS Fauci

1 vs. 2 Doses of H1N1 Vaccine in Healthy Populations 3 protocols Goal: rapid availability of immunogenicity data 2 doses,15µg or 30µg, 21 days apart SP and CSL vaccine adult trials (n = 400 each protocol) 100 adults (18-64y), 100 elderly (65y+); per dose group SP vaccine pediatric trial (N = 600) children (6mo to < 36mo, 3y to 9y, 10y to 17y) 100 per dose group in each age stratum endpoints: safety and immunogenicity SAEs, AEs - 6 months post dose 2 4-fold rises, proportion with titer ≥ 1:40 by HAI at day 21, 42 early immunogenicity data points - post each dose additional blood draws: 8 to 10 days subset of vaccinated subjects Lead PIs: Pat Winokur, UIowa; Karen Kotloff, UMD 3 protocols Goal: rapid availability of immunogenicity data 2 doses,15µg or 30µg, 21 days apart SP and CSL vaccine adult trials (n = 400 each protocol) 100 adults (18-64y), 100 elderly (65y+); per dose group SP vaccine pediatric trial (N = 600) children (6mo to < 36mo, 3y to 9y, 10y to 17y) 100 per dose group in each age stratum endpoints: safety and immunogenicity SAEs, AEs - 6 months post dose 2 4-fold rises, proportion with titer ≥ 1:40 by HAI at day 21, 42 early immunogenicity data points - post each dose additional blood draws: 8 to 10 days subset of vaccinated subjects Lead PIs: Pat Winokur, UIowa; Karen Kotloff, UMD v

Co- or Sequential Administration of H1N1 and ‘09-’10 TIV 2 protocols: safety and immunogenicity of co- and sequential administration of inactivated H1N1 vaccine and TIV H1N1 vaccine before, after, or at the same time as TIV 2 doses,15 µg sanofi pasteur H1N1 vaccine, 21 days apart 1 dose TIV 400 adults (18-64y), 400 elderly (65y+) 600 primed children (50 per group) 6mo to < 36mo, 3y to 9y, 10y to 18y unprimed children - finalizing protocol endpoints: safety and immunogenicity SAEs, AEs - 6 months post dose 2 4-fold rises, proportion with titer ≥ 1:40 by HAI Lead PI: Sharon Frey, St. Louis VTEU 2 protocols: safety and immunogenicity of co- and sequential administration of inactivated H1N1 vaccine and TIV H1N1 vaccine before, after, or at the same time as TIV 2 doses,15 µg sanofi pasteur H1N1 vaccine, 21 days apart 1 dose TIV 400 adults (18-64y), 400 elderly (65y+) 600 primed children (50 per group) 6mo to < 36mo, 3y to 9y, 10y to 18y unprimed children - finalizing protocol endpoints: safety and immunogenicity SAEs, AEs - 6 months post dose 2 4-fold rises, proportion with titer ≥ 1:40 by HAI Lead PI: Sharon Frey, St. Louis VTEU

Mixing and Matching Vaccines, Adjuvants HHS 2009 H1N1 vaccine strategy Assess safety and immunogenicity mixing stockpiled vaccine antigen and adjuvants from different manufacturers vaccines: CSL and sanofi pasteur H1N1 vaccine adjuvant: GSK’s AS03 mixed prior to administration protocol: 3.75µg +AS03, 7.5ug and 15µg +/- AS03 2 doses, 21 days apart status: submit IND for sanofi pasteur/AS03 study within a week; CSL/AS03 study to follow Lead PIs: Lisa Jackson (Seattle Group Health) and Kathryn Edwards (Vanderbilt) HHS 2009 H1N1 vaccine strategy Assess safety and immunogenicity mixing stockpiled vaccine antigen and adjuvants from different manufacturers vaccines: CSL and sanofi pasteur H1N1 vaccine adjuvant: GSK’s AS03 mixed prior to administration protocol: 3.75µg +AS03, 7.5ug and 15µg +/- AS03 2 doses, 21 days apart status: submit IND for sanofi pasteur/AS03 study within a week; CSL/AS03 study to follow Lead PIs: Lisa Jackson (Seattle Group Health) and Kathryn Edwards (Vanderbilt)

Other studies Additional H1N1 vaccine studies Protocols in development pregnant women Safety and immunogenicity of TIV in pregnant women trial initiated June 11, 2009 in VTEUs and subcontract sites 2 nd and 3 rd trimester women single dose TIV ( Fluzone, Fluarix) antibody responses: HAI 41 women enrolled as of July 22 nd, 2009 PI: Shitel Patel, Baylor Fall 2009 planned follow on study with TIV 4 licensed US manufacturers of inactivated vaccine Additional H1N1 vaccine studies Protocols in development pregnant women Safety and immunogenicity of TIV in pregnant women trial initiated June 11, 2009 in VTEUs and subcontract sites 2 nd and 3 rd trimester women single dose TIV ( Fluzone, Fluarix) antibody responses: HAI 41 women enrolled as of July 22 nd, 2009 PI: Shitel Patel, Baylor Fall 2009 planned follow on study with TIV 4 licensed US manufacturers of inactivated vaccine

ACKNOWLEDGEMENTS DHHS H1N1 vaccines for NIH trials under BARDA contract FDA CDC Manufacturers VTEU investigators EMMES Corporation SRI Birmingham Fisher Bioservices PPD Independent Safety Committee members NIAID and DMID colleagues DHHS H1N1 vaccines for NIH trials under BARDA contract FDA CDC Manufacturers VTEU investigators EMMES Corporation SRI Birmingham Fisher Bioservices PPD Independent Safety Committee members NIAID and DMID colleagues